Are intravenous corticosteroids required in status asthmaticus?

Area of Science:

• Pulmonology
• Clinical Pharmacology

Background:

• Status asthmaticus is a severe asthma exacerbation requiring prompt treatment.
• Methylprednisolone is a corticosteroid commonly used in asthma management.
• The route of administration (oral vs. intravenous) for methylprednisolone in status asthmaticus requires further investigation.

Purpose of the Study:

• To compare the efficacy and safety of oral versus intravenous methylprednisolone in patients with status asthmaticus.
• To evaluate the impact of administration route on pulmonary function recovery and hospitalization duration.

Main Methods:

• A prospective study involving 77 patients with status asthmaticus.
• Randomized assignment to receive daily oral (160 or 320 mg) or intravenous (500 or 1000 mg) methylprednisolone.
• Spirometry performed at baseline, every six hours for 24 hours, then every 8-12 hours until discharge or 72 hours.

Main Results:

• No significant differences were observed between oral and intravenous methylprednisolone groups regarding respiratory failure incidence, forced expiratory volume in 1 second (FEV1) improvement, hospitalization duration, or side effects.
• Pulmonary function recovery rates were comparable across both treatment groups.
• All patients experiencing respiratory failure did so within three hours of the initial steroid dose.

Conclusions:

• Oral methylprednisolone is a safe and effective alternative to intravenous administration for treating status asthmaticus.
• The findings suggest that oral corticosteroids can be reliably used in emergency asthma care settings.
• This study provides evidence to support a shift towards oral methylprednisolone for managing severe asthma exacerbations.